Document is current
Any future updates will be listed below
-
Authors
Yong, Xiaolan
He, Jianxing
Zhang, Caroline
Wang, Yongji
Ou, Yoko
Zhang, Biliang
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05897190 at ClinicalTrials.govDocuments that mention this clinical trial
Heterologous RBMRNA-405 mRNA booster enhances humoral immunity post-inactivated COVID-19 vaccination: a randomized clinical trial in adults and older through 12 months
https://doi.org/10.1038/s41598-026-45429-w
-
Funding
Funding for this research was provided by:
Argorna Pharmaceuticals Co., Ltd
- License Information
-
More Information
Article History
Received: 10 June 2025
Accepted: 18 March 2026
First Online: 25 March 2026
Competing interests
: This study was an investigator-initiated trial (IIT). The sponsor/funder had no role in study design, data collection, data analysis, data interpretation, or writing of the trial report. This trial was sponsored by Argorna Pharmaceuticals, which provided the study vaccine RBMRNA-405. RBMRNA-405 was co-developed by Argorna and RiboBio. YO and BZ are employees of Argorna. CZ is an employee of RiboBio. The other authors declare no competing interests.
